Product image of Lecigimon (Entacapone, Levodopa, Carbidopa Monohydrate) supplied by GNH India

Lecigimon

Active Ingredient:
Entacapone, Levodopa, Carbidopa Monohydrate
Origin:
EU

Lecigimon (Entacapone, Levodopa, Carbidopa Monohydrate)

Entacapone, Levodopa, Carbidopa, the active ingredients in Lecigimon, are a combination (MAO‑B inhibitor, DOPA decarboxylase inhibitor, dopamine precursor) presented as a combination tablet for intestinal use. It is indicated for the treatment of Parkinson's disease and related motor fluctuations in adult patients.
GNH India supplies Lecigimon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Lobsor Pharmaceuticals Ab

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lecigimon, a combination therapy for Parkinson’s disease, is indicated for:

  • Parkinson's disease: improves motor symptoms by increasing central dopamine levels.
  • Motor fluctuations in Parkinson's disease: reduces OFF time and enhances ON time.
  • Adjunct therapy for levodopa‑treated patients: stabilizes levodopa plasma concentrations and prolongs its clinical effect.

How It Works

  • Levodopa crosses the blood‑brain barrier and is converted to dopamine, restoring deficient neurotransmission in Parkinson's disease. Carbidopa inhibits peripheral DOPA decarboxylase, preventing premature conversion of levodopa and increasing its central availability. Entacapone blocks catechol‑O‑methyltransferase (COMT), reducing peripheral levodopa metabolism, thereby extending its plasma half‑life and enhancing overall efficacy.

Side Effects

Lecigimon may cause a range of adverse reactions. Patients should be informed of both common and serious possibilities.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Dyskinesia: involuntary movements, especially at higher levodopa doses.
  • Orthostatic hypotension: dizziness upon standing.
  • Constipation: reduced bowel motility.
  • Dizziness: sensation of light‑headedness.
  • Dry mouth: reduced salivation.

Serious or Rare Side Effects

  • Severe liver injury: elevated transaminases or hepatic failure.
  • Neuroleptic malignant syndrome: high fever, muscle rigidity, autonomic instability.
  • Severe allergic reactions: rash, angioedema, anaphylaxis.
  • Hyperpyrexia: dangerously high body temperature.
  • Severe depression or suicidal thoughts.
  • Hallucinations: visual or auditory disturbances.

Precautions & Warnings

Before initiating Lecigimon, clinicians should consider several safety measures.

  • Monitor hepatic function: assess liver enzymes periodically.
  • Assess for dyskinesia: adjust levodopa dose if excessive movements develop.
  • Caution in elderly patients: increased risk of orthostatic hypotension and confusion.
  • Avoid in patients with narrow‑angle glaucoma: may exacerbate intra‑ocular pressure.
  • Review concomitant MAO‑B inhibitors: risk of hypertensive crisis.
  • Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Lecigimon can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

  • Non‑selective MAO inhibitors: may precipitate hypertensive crisis.
  • Anticholinergic agents: can increase anticholinergic burden and cognitive impairment.
  • Dopamine agonists: may potentiate dyskinesia and psychosis.

Moderate Interactions (Monitor Closely)

  • Antihypertensive drugs: may enhance hypotensive effects.
  • Iron or calcium supplements: can reduce levodopa absorption if taken simultaneously.
  • High‑protein meals: may compete with levodopa transport, decreasing its bioavailability.

Frequently Asked Questions

Lecigimon is a prescription combination of entacapone, levodopa and carbidopa used to treat Parkinson's disease and to manage motor fluctuations in patients already receiving levodopa therapy. It helps improve motor control and reduces periods when symptoms return (OFF time).

Levodopa is a precursor that the brain converts into dopamine, restoring deficient neurotransmission. Carbidopa blocks peripheral conversion of levodopa, increasing the amount that reaches the brain. Entacapone inhibits the COMT enzyme, slowing levodopa breakdown and extending its therapeutic effect.

The dosage of Lecigimon is individualized. A qualified prescriber determines the appropriate strength, frequency and total daily dose based on the patient’s clinical condition, response to therapy and tolerability. Patients should follow the prescribing information provided by their healthcare professional.

Safety of Lecigimon in pregnancy or while breastfeeding has not been established. The product should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by the prescribing clinician.

To request Lecigimon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Lecigimon combines a COMT inhibitor (entacapone) with levodopa and carbidopa, offering longer levodopa exposure than levodopa/carbidopa alone. Compared with dopamine agonists, it provides a more direct dopamine replacement but may have a higher risk of dyskinesia. Choice of therapy depends on individual patient factors and physician judgment.

Lecigimon should be stored at room temperature, below 25 °C, in its original packaging. Keep the tablets away from moisture, heat and direct sunlight to maintain stability and potency throughout its shelf life.

Lecigimon is taken orally, usually with food to reduce gastrointestinal irritation. The tablets are swallowed whole with a glass of water. Dosing schedules are set by the prescriber, often divided into multiple daily doses to maintain steady plasma levels.

Serious risks include severe liver injury, neuroleptic malignant syndrome, severe allergic reactions (including anaphylaxis), hyperpyrexia, and worsening psychiatric symptoms such as severe depression or suicidal thoughts. Patients should be monitored closely for any of these events.

Lecigimon is contraindicated in patients taking non‑selective MAO inhibitors, those with narrow‑angle glaucoma, or individuals with known hypersensitivity to any component of the product. It should also be used with caution in patients with significant hepatic impairment or a history of severe psychiatric illness.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Entacapone, Levodopa, Carbidopa Monohydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT